Brief: Todos Medical Announces Positive Biomarker Data From Phase 2 Trial Of Tollovir In Hospitalized COVID Patients
30/06/2022 12:53
June 30 (Reuters) - Todos Medical Ltd TOMDF.PK :
* TODOS MEDICAL ANNOUNCES POSITIVE BIOMARKER DATA FROM PHASE
2
TRIAL OF TOLLOVIR IN HOSPITALIZED COVID-19 PATIENTS
* TODOS MEDICAL LTD - BIOMARKER DATA CORRELATES WITH
CLINICAL DATA
ANNOUNCED IN JANUARY 2022
* TODOS MEDICAL LTD - RENAL AND HEPATIC BIOMARKER DATA
SHOWED NO
SIGNALS OF TREATMENT-ASSOCIATED RISK WITH TOLLOVIR THERAPY
Source text for Eikon: ID:nGNX2LBLWL
Further company coverage: TOMDF.PK
Recent news on Todos Medical
See all newsBrief: Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network
Brief: Todos Medical Clia/Cap Lab Provista Submits Emergency Use Authorization Application For Monkeypox Pcr Test To Us FDA
Brief: Todos Medical Provides Corporate Update
Brief: Todos Medical Enters Into $50 Mln Contract To Supply Tollovid, CBD Products To Retail Distributor Company Nerd Hemp
Brief: Todos Medical Establishes Botanical Supplement Manufacturing Capabilities